PARIS, February 26 /PRNewswire-FirstCall/ -- ExonHit Therapeutics (Alternext: ALEHT) is pleased to announce that clinical testing of EHT 0202, its lead compound in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results